WO2005053730A1 - 末期心不全治療剤 - Google Patents
末期心不全治療剤 Download PDFInfo
- Publication number
- WO2005053730A1 WO2005053730A1 PCT/JP2004/018008 JP2004018008W WO2005053730A1 WO 2005053730 A1 WO2005053730 A1 WO 2005053730A1 JP 2004018008 W JP2004018008 W JP 2004018008W WO 2005053730 A1 WO2005053730 A1 WO 2005053730A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heart failure
- therapeutic agent
- stage heart
- stimulating factor
- granulocyte colony
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Definitions
- the present invention relates to a therapeutic agent for end-stage heart failure comprising granulocyte colony-stimulating factor (hereinafter abbreviated as G-CSF) as an active ingredient.
- G-CSF granulocyte colony-stimulating factor
- hypertrophy The case where individual cardiomyocytes become larger than physiological growth in response to various stimuli including hemodynamic loads such as hypertension and myocardial infarction is called hypertrophy.
- the heart as an organ causes (1) afferent cardiac hypertrophy or (2) efferent diastole.
- pressure overload such as hypertension or hypertrophic cardiomyopathy is (1), the ventricular wall thickens and diastolic function is impaired (diastolic dysfunction), but contractile function is maintained.
- cases of diminished left ventricular contractility such as dilated cardiomyopathy or remodeling after myocardial infarction are (2), in which the ventricular wall is thinned and the lumen expands.
- These (1) and (2) are often present in a mixed form and are called chronic heart failure, with decreased exercise tolerance and arrhythmia.
- the resting cardiac output is normal, blood flow to various organs is maintained, and there is a limited but compensated state.
- the case where this compensation is temporarily lost but reversible is called acute exacerbation of chronic heart failure (acute heart failure). Threshold), and eventually the cardiac output decreases even at rest, resulting in decreased blood flow to whole-body storage, pulmonary congestion, and death.
- Such a condition is called end-stage heart failure and is a common final picture of various heart diseases such as hypertensive disease, idiopathic cardiomyopathy, and ischemic heart disease.
- the present inventors examined whether the cardiac function and prognosis were improved in a nomster model reflecting end-stage heart failure, and found that administration of G-CSF resulted in heart failure in end-stage heart failure. Improvement of the function and increase of the survival rate were confirmed, and the present invention was completed.
- the present invention provides a therapeutic agent for end-stage heart failure containing human G-CSF as an active ingredient, and a pharmaceutical composition containing the therapeutic agent.
- FIG. 1 shows the left ventricular ejection fraction (LVEF%) after administration in a G-CSF administration group and a control group.
- G-CSF Granulocyte colony-stimulating factor
- neutrophil progenitor cells acts on neutrophil progenitor cells to promote their differentiation and proliferation, and also promotes the release of mature neutrophils from bone marrow and enhances neutrophil function Because it has an effect, it is a protein that has already been clinically applied as a therapeutic agent for neutropenia after hematopoietic stem cell transplantation or as a therapeutic agent for neutropenia after cancer chemotherapy. In addition, it has the effect of mobilizing hematopoietic stem cells in bone marrow into peripheral blood, It has also been clinically applied as an agent for mobilizing hematopoietic stem cells into peripheral blood when collecting autologous peripheral blood stem cells.
- G-CSF improves cardiac function and increases the survival rate of patients with end-stage heart failure.
- end-stage heart failure refers to a state of severe heart failure that requires a heart transplant.
- LVEF left ventricular ejection fraction
- NYHA New York It corresponds to degree III / IV in the heart function classification of the Heart Association
- degrees III and IV of the NYHA classification refer to the following conditions.
- degree III there is a heart disease, and physical activity is significantly restricted. There are no complaints at rest, but relatively light daily exertion can cause dyspnea, angina, fatigue, and palpitations.
- Degree IV There is a heart disease, and the above-mentioned complaints appear during any degree of physical exertion. In addition, heart failure symptoms or angina pectoris syndrome can be seen even at rest. Strengthen.
- Biol4.6 Cardiomyopathy hamsters As a model animal corresponding to such a state of end-stage heart failure in humans, for example, sold by Charles Brewers, manufactured by Bio Breeders! /, A state of a Biol4.6 cardiomyopathy hamster over 50 weeks of age Is mentioned. Biol4.6 Cardiomyopathy hamsters from 20 to 30 weeks of age are supplied as hypertrophic cardiomyopathy models.At least over 50 weeks of age, contractility is reduced and blood flow to various organs is reduced. , From pulmonary congestion to death. In rodents such as hamsters, the normal value of the ejection fraction is about 90%, and in end-stage heart failure it is about 60%.
- the present inventors examined whether cardiac function and prognosis were improved in a 51-week-old Biol4.6 cardiomyopathy hamster model reflecting such end-stage heart failure.
- Administration of a lower dose of 4 / zg / kg G-CSF improves cardiac function and increases survival in end-stage heart failure, compared to administration of G-CSF ⁇ 10 g / kg It was confirmed.
- the therapeutic agent for end-stage heart failure of the present invention is useful for individuals with established end-stage heart failure. It is intended to be administered prophylactically to patients before end-stage heart failure.
- G-CGF that can be used in the present invention
- human G-CSF examples include, for example, a polypeptide having human G-CSF activity represented by the amino acid sequence of SEQ ID NO: 13 or a glycoprotein having a sugar chain attached thereto.
- G-CSF derivatives having G-CSF activity in which a part of the amino acid sequence having the same sequence is modified are also included in the G-CSF of the present invention.
- These G-CSFs are preferably those obtained by force gene recombination, including those of natural origin and those obtained by genetic recombination.
- host cells include Escherichia coli and mammalian cells (C127, CHO cells, etc.). Details of these production methods are described in, for example, JP-T-63-500636, JP-A-62-236497, and JP-A-62-236497.
- polypeptide or glycoprotein represented by the amino acid sequence of SEQ ID NO: 13 and the G-CSF derivative a copolymer of polyethylene glycol, ethylene glycol Z propylene glycol, carboxymethyl cellulose, dextran, polybutyl alcohol, etc. (See, for example, WO90 / 06952, W096 / 11953,
- the sugar chain binding site by modifying the sugar chain binding site, the sugar chain structure is changed, or a modified G-CSF sugar chain in which a sugar chain is added or deleted, or albumin, vitamin B12, or immune Proteins fused with globulin and the like are also included.
- a modified G-CSF sugar chain in which a sugar chain is added or deleted, or albumin, vitamin B12, or immune Proteins fused with globulin and the like are also included.
- PEG ⁇ G-CSF G-CSF conjugated with polyethylene glycol
- Amgen as Neulasta registered trademark
- the therapeutic agent for end-stage heart failure of the present invention can be administered alone or as a pharmaceutical composition containing a pharmaceutically acceptable carrier, excipient, stabilizer and the like.
- a pharmaceutical composition can be in the form of sustained-release preparations such as injection preparations, oral preparations, transmucosal preparations, and any of the forms commonly used in the art. Particularly preferred are injection preparations.
- the route of administration for injection preparations includes subcutaneous administration, intravenous administration, intramuscular administration, intracoronary administration, and administration using sustained release gel. Particularly preferred is subcutaneous administration and intravenous administration.
- the dose and frequency of administration of G-CSF can be determined according to the condition of the patient, and are not particularly limited, but are usually 0.01 to 100 / zg /. kg / day, preferably 0.1-g / kg / day, and can be administered for 17 weeks for 17 weeks.
- the therapeutic agent for end-stage heart failure of the present invention may also be used as a conventional therapeutic agent for severe heart failure such as ⁇ -receptor blocker, angiotensin converting enzyme inhibitor, angiotensin II receptor antagonist, aldosterone antagonist and the like. It can be used in combination with the drug used, human growth hormone, or one or more growth factors such as VEGF, bFGF, and HGF.They can be administered simultaneously or separately, or contain both. It can also be administered as a pharmaceutical composition. These drugs, which have no effect on end-stage cardiac failure alone, can also be effective when administered to patients whose cardiac function has been improved by G-CSF.
- the therapeutic effect on end-stage heart failure can be confirmed by, for example, an improvement in left ventricular ejection fraction, an improvement in mortality, an improvement in exercise tolerance, a reduction in arrhythmia, and the like.
- the therapeutic agent for end-stage heart failure of the present invention can improve the condition of end-stage heart failure patients by pharmacotherapy without requiring surgical treatment, but is performed as an adjuvant treatment before treatment such as heart transplantation. Talk about this.
- Bio-4.6 cardiomyopathy hamsters (Bio Breeders, 51 weeks old) were treated with 4 ⁇ g / kg human G-CSF (Filgrastim, Kirin Brewery, peptide represented by the amino acid sequence of SEQ ID NO: 1) or physiological saline Water was injected subcutaneously three days a week (Monday, Wednesday, Friday) and hemodynamic evaluation was performed by echocardiography 8 weeks later.
- human G-CSF Frgrastim, Kirin Brewery, peptide represented by the amino acid sequence of SEQ ID NO: 1
- physiological saline Water was injected subcutaneously three days a week (Monday, Wednesday, Friday) and hemodynamic evaluation was performed by echocardiography 8 weeks later.
- the left ventricular ejection fraction (LVEF) was significantly (p ⁇ 0.05) 4 ⁇ g compared with the group administered with 4 ⁇ g / kg G-CSF and the physiological saline. High strength was observed in the G / CSF / kg administration group (see Fig. 1). The heart rate also showed a higher tendency in the G-CSF group (mean 380 beats / min) than in the physiological saline group (mean 327 beats / min), and the activity was also higher in the G-CSF group. I was obviously strong.
- the present invention is useful as a therapeutic means that does not require surgical treatment for end-stage heart failure, which conventionally requires a heart transplant or the like!
- SEQ ID NO: 1 Description of artificial sequence: amino acid sequence containing Met residue at position -1 with respect to naturally occurring human G-CSF
- SEQ ID NO: 3 Description of artificial sequence: Met residue at position -1 relative to naturally occurring human G-CSF, and Thr residue at position +1; Leu residue at position +3; Gly at position +4 Residue, Pro residue at position +5 and Cys residue at position +17 are substituted with Ala, Thr, Tyr, Arg and Ser residues, respectively.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-408002 | 2003-12-05 | ||
JP2003408002 | 2003-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005053730A1 true WO2005053730A1 (ja) | 2005-06-16 |
Family
ID=34650330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/018008 WO2005053730A1 (ja) | 2003-12-05 | 2004-12-03 | 末期心不全治療剤 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005053730A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01316400A (ja) * | 1988-03-31 | 1989-12-21 | Kyowa Hakko Kogyo Co Ltd | 修飾ポリペプチド |
WO1990006952A1 (en) * | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
WO1996011953A1 (en) * | 1994-10-12 | 1996-04-25 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
JPH08198772A (ja) * | 1994-11-25 | 1996-08-06 | Kirin Brewery Co Ltd | 顆粒球コロニー刺激因子含有粉末経鼻投与製剤 |
-
2004
- 2004-12-03 WO PCT/JP2004/018008 patent/WO2005053730A1/ja not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01316400A (ja) * | 1988-03-31 | 1989-12-21 | Kyowa Hakko Kogyo Co Ltd | 修飾ポリペプチド |
WO1990006952A1 (en) * | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
WO1996011953A1 (en) * | 1994-10-12 | 1996-04-25 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
JPH08198772A (ja) * | 1994-11-25 | 1996-08-06 | Kirin Brewery Co Ltd | 顆粒球コロニー刺激因子含有粉末経鼻投与製剤 |
Non-Patent Citations (7)
Title |
---|
HIROTA Y. ET AL: "Shinfuzen no Shindan to Hyoka no Susumekata", MEDICINA, vol. 33, no. 5, 1996, pages 858 - 861, XP002996982 * |
LI Y. ET AL: "Granulocyte-Colony Stimulating Factor (G-CSF) improves function of the hearts with established heart failure due to large old myocardial infarction", CIRCULATION JOURNAL, vol. 67, no. 1, 1 March 2003 (2003-03-01), pages 335, XP002983783 * |
MINATOGUCHI N. ET AL: "Shinkin Saibo Saisei ni yoru Shinkin Kosoku Chiryo", SAISEI IRYO, vol. 2, no. 1, 2003, pages 15 - 18, XP002996981 * |
OMAY S. ET AL: "Autologous peripheral stem cell transplantation in patients with congestive heart failure due to ischemic heart disease", BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), pages 151 - B, XP002983782 * |
ORLIC D. ET AL: "Mobilized bone marrow cells repair the infarcted heart, improving function and survival", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 18, 2001, pages 10344 - 10349, XP002950780 * |
TAKANO H. ET AL: "Pleiotropic effects of cytokines on acute myocardial infarction: G-CSF as a novel therapy for acute myocardial infarction", CURRENT PHARMACEUTICAL DESIGN, vol. 9, no. 14, 2003, pages 1121 - 1127, XP009042575 * |
TARELLA C. ET AL: "Transmyocardial Scarification Associated with Peripheral Blood Stem Cell (PBSC) Mobilization: A Pilot Study in Patients with End-Stage Cardiac Failure Due to Coronary Artery Disease", BLOOD, vol. 100, no. 11, 2002, pages 38 - A, XP002983781 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230120030A1 (en) | Long-Acting Adrenomedullin Derivatives | |
US7816321B2 (en) | Thymosin β4 derivatives and use thereof | |
JP2003519097A (ja) | 脈管形成因子の用量および心筋血流を改善するための投与方法 | |
KR20070007842A (ko) | 신장증가용 조성물 | |
JP2001288112A (ja) | 虚血性疾患の処置又は予防に用いる医薬組成物 | |
JP2003519097A5 (ja) | ||
JP2000500492A (ja) | Ob蛋白組成物を用いる非脂肪組織重増加方法 | |
EP1948246B1 (en) | Stem cell factor therapy for tissue injury | |
WO2000021548A2 (en) | Angiogenically effective unit dose of fgf and method of administering | |
US20020032153A1 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
JP2019508378A (ja) | 昇圧薬の投与方法 | |
JPH08505617A (ja) | インシュリン状成長因子を含有する安定溶液 | |
ES2933405T3 (es) | Tratamiento de complicaciones vasculares de diabetes | |
US9101593B2 (en) | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment | |
JP6824888B2 (ja) | 筋肉の疾患および障害を治療するための方法および組成物 | |
US20020019352A1 (en) | Stable, active, human ob protein compositions and methods | |
AU2018244776B2 (en) | Methods of treatment for kidney disease | |
WO2005053730A1 (ja) | 末期心不全治療剤 | |
SG174966A1 (en) | Compositions and methods for treatment of aortic fibrosis | |
JP2005206544A (ja) | 筋肉再生剤 | |
US8703693B2 (en) | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment | |
KR20210127215A (ko) | 호중구 감소증을 예방하거나 또는 호중구 감소증의 지속기간을 감소시키기 위한 지속성 g-csf | |
JP4114979B2 (ja) | 拡張型心筋症治療剤 | |
US20120129772A1 (en) | Soluble igf receptors as anti-angiogenic agents | |
WO2021112207A1 (ja) | 急性期脳梗塞患者における脳梗塞の症状を治療するための医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |